Pharma

Your Article Summary

See Latest Articles

Enzon Commences Phase II Trial of PEG-SN38
Enzon Pharmaceuticals, 06/23/09

Enzon Pharmaceuticals, Inc. announced that it has opened its first Phase II trial for PEG-SN38, its novel proprietary cancer compound. The trial is open at multiple centers throughout the United States for patients diagnosed with metastatic colon cancer.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09

See All of Drug Trials